Figure 2.
The effects of bortezomib on intracellular signaling–mediating molecules in EBV+T- or NK-cell lines. (A-C) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 24 hours and subjected to immune blotting. Hsp90 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control. (D) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 24 hours. The expression and the localization of NF-κB proteins were examined by immune-fluorescent staining with anti-p50, p52, RelA, and RelB antibodies. DAPI was for nuclei; original magnification ×60. The cells were analyzed by confocal microscopy.

The effects of bortezomib on intracellular signaling–mediating molecules in EBV+T- or NK-cell lines. (A-C) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 24 hours and subjected to immune blotting. Hsp90 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control. (D) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 24 hours. The expression and the localization of NF-κB proteins were examined by immune-fluorescent staining with anti-p50, p52, RelA, and RelB antibodies. DAPI was for nuclei; original magnification ×60. The cells were analyzed by confocal microscopy.

Close Modal

or Create an Account

Close Modal
Close Modal